The NCCN Clinical Practice Guidelines provide comprehensive recommendations for the risk evaluation, diagnosis, prevention, and treatment of venous thromboembolism in patients with cancer.
Directs VTE management decisions in cancer patients now; extends prior consensus with updated risk-based recommendations.
Venous thromboembolism (VTE) remains a common and life-threatening complication among patients with cancer. Thromboprophylaxis can be used to prevent the occurrence of VTE in patients with cancer who are considered at high risk for developing this complication. Therefore, it is critical to recognize the various risk factors for VTE in patients with cancer. Risk assessment tools are available to help identify patients for whom discussions regarding the potential benefits and risks of thromboprophylaxis would be appropriate. The NCCN Clinical Practice Guidelines in Oncology for VTE provide recommendations on risk evaluation, diagnosis, prevention, and treatment of VTE in patients with cancer.
No takes yet. Share an insight, caveat, or question.
Streiff et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: